Moderna shares fall after FDA refuses to review influenza vaccine application
The FDA said in its refusal letter that the company's approach to compare mRNA-1010 to an already licensed standard-dose seasonal influenza was the only reason why it declined to initiate a review of the application.
The FDA said in its refusal letter that the company's approach to compare mRNA-1010 to an already licensed standard-dose seasonal influenza was the only reason why it declined to initiate a review of the application.
What's Your Reaction?
DDP Editor
Admin managing news updates, RSS feed curation, and PR content publishing. Focused on timely, accurate, and impactful information delivery.
